Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer - PubMed (original) (raw)
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer
Laine J Murphey et al. Anal Biochem. 2004.
Abstract
Prostaglandin (PG)E2 is a major cyclooxygenase (COX) product that is important in human physiology and pathophysiology. Quantification of systemic PG production in humans is best assessed by measuring excreted urinary metabolites. Accurate and easy-to-perform assays to quantify the major urinary metabolite of PGE2, 11alpha-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), do not exist. We now report the development of a robust and facile method to measure urinary PGE-M excretion in humans using stable isotope dilution techniques employing liquid chromatography/tandem mass spectrometry (LC/MS/MS). Concentrations of the metabolite in urine from healthy humans are nearly twofold greater in men than in women (10.4+/-1.5 vs. 6.0+/-0.7 ng/mg creatinine). Levels of PGE-M in healthy humans are suppressed significantly not only by the nonselective COX inhibitor ibuprofen but also by the COX-2 selective inhibitor rofecoxib, suggesting that the majority of PGE2 formed in vivo is derived from COX-2. Increased COX-2 expression and increased PGE2 production are associated with malignancy. Levels of PGE-M were found to be greatly increased in humans with unresectable non-small cell cancer of the lung, and this increase is dramatically reduced by administration of the COX-2 inhibitor celecoxib, implying that COX-2 contributes significantly to the overproduction of PGE2. In summary, quantification of PGE-M using LC/MS/MS provides a facile and accurate method to assess PGE2 formation in human physiological and pathophysiological processes.
Similar articles
- Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine.
Neale JR, Dean BJ. Neale JR, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Aug 1;871(1):72-7. doi: 10.1016/j.jchromb.2008.06.042. Epub 2008 Jul 1. J Chromatogr B Analyt Technol Biomed Life Sci. 2008. PMID: 18632314 - Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH. Csiki I, et al. Clin Cancer Res. 2005 Sep 15;11(18):6634-40. doi: 10.1158/1078-0432.CCR-05-0436. Clin Cancer Res. 2005. PMID: 16166442 Clinical Trial. - Cyclooxygenase as a target in lung cancer.
Brown JR, DuBois RN. Brown JR, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4266s-4269s. doi: 10.1158/1078-0432.CCR-040014. Clin Cancer Res. 2004. PMID: 15217972 Review. - [Cyclooxygenase 2 inhibitors and lung carcinoma].
Spano JP, Chouahnia K, Morère JF. Spano JP, et al. Bull Cancer. 2004 May;91 Spec No:S109-12. Bull Cancer. 2004. PMID: 15239338 Review. French.
Cited by
- Major urinary metabolites of 6-keto-prostaglandin F2α in mice.
Kuklev DV, Hankin JA, Uhlson CL, Hong YH, Murphy RC, Smith WL. Kuklev DV, et al. J Lipid Res. 2013 Jul;54(7):1906-14. doi: 10.1194/jlr.M037192. Epub 2013 May 3. J Lipid Res. 2013. PMID: 23644380 Free PMC article. - Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.
Kekatpure VD, Boyle JO, Zhou XK, Duffield-Lillico AJ, Gross ND, Lee NY, Subbaramaiah K, Morrow JD, Milne G, Lippman SM, Dannenberg AJ. Kekatpure VD, et al. Cancer Prev Res (Phila). 2009 Nov;2(11):957-65. doi: 10.1158/1940-6207.CAPR-09-0093. Epub 2009 Oct 20. Cancer Prev Res (Phila). 2009. PMID: 19843689 Free PMC article. - Quantification of eicosanoids and their metabolites in biological matrices: a review.
Chhonker YS, Bala V, Murry DJ. Chhonker YS, et al. Bioanalysis. 2018 Dec;10(24):2027-2046. doi: 10.4155/bio-2018-0173. Epub 2018 Nov 6. Bioanalysis. 2018. PMID: 30412686 Free PMC article. Review. - Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer.
Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Crew KD, et al. J Hum Nutr Diet. 2015 Jun;28(3):272-82. doi: 10.1111/jhn.12229. Epub 2014 Mar 19. J Hum Nutr Diet. 2015. PMID: 24646362 Free PMC article. Clinical Trial. - Targeting the eicosanoid pathway in non-small-cell lung cancer.
Horn L, Backlund M, Johnson DH. Horn L, et al. Expert Opin Ther Targets. 2009 Jun;13(6):675-88. doi: 10.1517/14728220902915567. Epub 2009 May 2. Expert Opin Ther Targets. 2009. PMID: 19409031 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- CA68485/CA/NCI NIH HHS/United States
- CA77839/CA/NCI NIH HHS/United States
- CA90949/CA/NCI NIH HHS/United States
- CA95103/CA/NCI NIH HHS/United States
- DK48831/DK/NIDDK NIH HHS/United States
- GM15431/GM/NIGMS NIH HHS/United States
- HL04445/HL/NHLBI NIH HHS/United States
- RR00095/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials